Tech Company Financing Transactions
Pahr Therapeutics Funding Round
Pahr Therapeutics, based in Boston, secured $14 million in investment from RA Capital Management and UTEC.
Transaction Overview
Company Name
Announced On
7/29/2025
Transaction Type
Venture Equity
Amount
$14,000,000
Round
Seed
Investors
RA Capital Management (Lead Investor)
Proceeds Purpose
The company intends to use the funds to develop new therapies for pulmonary arterial hypertension (PAH).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Boston, MA Undisclosed
USA
Boston, MA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
PAhR Therapeutics is a clinical-stage company focused on developing novel mechanisms for the treatment of pulmonary arterial hypertension (PAH)
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Founder
Ryotaro Asano
Founder
Neil Buckley
Founder
Yoshikazu Nakaoka
Founder
Makoto Okazawa
Browse more venture capital transactions:
Prev: 7/29/2025: Kinvard Bio venture capital transaction
Next: 7/29/2025: Fluid Focus venture capital transaction
Share this article
News on VC Transactions
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs